as of 08-25-2026 3:39pm EST
HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | SANTA CLARA |
| Market Cap: | 27.7M | IPO Year: | 2021 |
| Target Price: | $5.63 | AVG Volume (30 days): | 397.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.21 | EPS Growth: | 15.07 |
| 52 Week Low/High: | $0.47 - $4.00 | Next Earning Date: | 05-08-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 315.97% |
| P/E Ratio: | -2.30 | Index: | N/A |
| Free Cash Flow: | -14588000.0 | FCF Growth: | N/A |
See how BEAT stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "BEAT Heartbeam Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.